Pfizer Inc. (NYSE:PFE) announced today the completion of pneumonia case accrual in the Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA) 65 years of age and older. CAPiTA, the largest trial of its kind, was designed to evaluate whether Prevenar 13* (Pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed]) is effective in preventing community-acquired pneumonia (CAP) caused by the 13 pneumococcal serotypes included in the vaccine.
It is an event-driven clinical study, meaning that a pre-specified number of community-acquired, vaccine-type pneumococcal pneumonia cases have to occur among study participants before the results can be determined.
As specified in the study protocol, all remaining suspected cases currently in review will be fully processed to allow the database to be locked. This case processing will take several months to complete and will be performed by Julius Clinical, a spin-off of the Julius Center for Health Sciences and Primary Care, a division of the University Medical Center Utrecht in the Netherlands, where the study is being conducted. Pfizer will be blinded to the data during this period. Once unblinding occurs, Pfizer, Julius Clinical, and the primary investigator will review the data and disclose the top-line results, which is expected to occur in early 2014.
The approval of Prevnar 13 for use in adult 50 years and older, under the United States Food and Drug Administration’s accelerated approval program, was based on the surrogate endpoint of immunogenicity. To fulfill regulatory commitments under this program, Pfizer initiated the CAPiTA study, which is intended to determine the effectiveness in the prevention of pneumococcal pneumonia. CAPiTA is the largest double-blind, randomized, placebo-controlled efficacy trial in the prevention of CAP. It involves approximately 85,000 subjects aged 65 years and older
and is the first ever conducted with a conjugated vaccine to evaluate at this scale. The trial was conducted by the University Medical Center Utrecht, the Netherlands. Fifty-eight sentinel hospitals are utilized for surveillance of community-acquired pneumonia and invasive pneumococcal disease (IPD). The primary outcome measure for CAPiTA is related to the efficacy of Prevenar 13 and its ability to prevent a first episode of vaccine-type CAP caused by the 13 pneumococcal serotypes contained in the vaccine.
Secondary endpoints evaluate the ability of Prevenar 13 to prevent a first episode of vaccine-type IPD and prevent a first episode of non-bacteremic/non-invasive vaccine-type CAP.
Despite current vaccination efforts, there are believed to be approximately 440,000 cases of pneumococcal pneumonia annually in the U.S. alone,
which results in 25,000 pneumococcal disease-related deaths annually.
About Prevenar 13
Prevenar 13 was first introduced for use in infants and young children in December 2009 in Europe and is now approved for such use in more than 120 countries worldwide, including the U.S. and Japan. It is the most widely used pneumococcal conjugate vaccine (PCV) in the world, and more than 575 million doses of Prevenar/Prevenar 13 have been distributed worldwide. In addition, Prevenar 13 is approved for use in adults 50 years of age and older in more than 90 countries, and is also approved in the U.S. and European Union (EU) for use in older children and adolescents aged 6 to 17 years. Recently, Prevenar 13 was also approved in the EU for use in adults 18 to 49 years of age, making it the only pneumococcal vaccine in the EU approved to help protect against IPD from infancy through adulthood.